Influenza Transmission Research Consortium (P01 Clinical Trial Optional)
ID: 359193Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359193
Timeline
    Description

    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Influenza Transmission Research Consortium (P01 Clinical Trial Optional)" aimed at advancing research on the mechanisms of human-to-human transmission of seasonal influenza virus. This initiative seeks to establish a network of Influenza Transmission Research Centers that will foster collaborative, multidisciplinary teams to investigate the dynamics and drivers of influenza transmission, ultimately developing novel resources for the field of respiratory virus transmission. With an estimated total program funding of $8 million and the expectation of awarding three grants, interested applicants are encouraged to begin forming collaborations and preparing their proposals ahead of the anticipated application solicitation, which is expected to open in September 2025. For further inquiries, potential applicants can contact Brooke Bozick, Ph.D., at brooke.bozick@mail.nih.gov or by phone at 301-761-6710.

    Point(s) of Contact
    Brooke Bozick, Ph.D. National Institute of Allergy and Infectious Diseases (NIAID)
    (301) 761-6710
    brooke.bozick@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Impact of Initial Influenza Exposure on Immunity in Infants
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Impact of Initial Influenza Exposure on Immunity in Infants," aimed at advancing research on how influenza infections and vaccinations affect infant and childhood immunity. The initiative seeks to establish and characterize longitudinal cohorts of infants and mother-infant dyads to investigate the influence of initial exposure to influenza antigens on immune responses to subsequent infections and vaccinations. This research is critical for developing durable and broadly protective influenza vaccines. The estimated total program funding is $10 million, with three awards expected, and interested applicants can reach out to Dr. Michelle M. Arnold at michelle.arnold@nih.gov or by phone at 301-761-7324. Key deadlines include an estimated synopsis close date of February 11, 2026, and an estimated award date of December 1, 2026.
    Tuberculosis Research Units (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the establishment of multidisciplinary Tuberculosis Research Units (TBRUs) through a grant program aimed at enhancing the understanding of Mycobacterium tuberculosis (Mtb) and its interactions with the host. This initiative seeks to foster collaborative research that characterizes the roles of bacterial and host heterogeneity in infection outcomes and disease progression, with a focus on identifying determinants relevant to Mtb establishment and dissemination. The total estimated program funding is $10 million, with approximately five awards expected, and interested applicants are encouraged to begin forming collaborations in anticipation of the Notice of Funding Opportunity (NOFO) expected to be published in September 2025. For further inquiries, potential applicants can contact Richard T. Robinson, Ph.D., at richard.robinson@nih.gov or by phone at 202-607-8565.
    Influenza Modeling and Forecasting
    Centers for Disease Control - NCIRD
    The Centers for Disease Control and Prevention (CDC) is forecasting a funding opportunity titled "Influenza Modeling and Forecasting," aimed at establishing a network to enhance the CDC's capabilities in influenza modeling and forecasting. The primary objective is to improve situational awareness, inform prevention and control strategies, advance the science of influenza forecasting, and facilitate communication of results with public health officials, particularly for populations disproportionately affected by influenza. The estimated total program funding is $11,250,000, with six awards expected, and applications must be submitted electronically by January 20, 2025. For further inquiries, interested applicants can contact Justin Lushbaugh at 404.498.3036 or via email at xko0@cdc.gov.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Viral INfections in the Young Lung (VINYL) Clinical Consortium, aimed at supporting research on severe viral lower respiratory tract infections (LRTI) in children aged 0-2 years. This initiative will involve the establishment of a consortium to phenotype affected children and follow them until preschool age to assess pulmonary sequelae, utilizing a phased award structure to fund various centers, including a Data and Analytics Coordinating Center and multiple Clinical Centers. The total funding available is projected to be up to $31.6 million, with the NOFO expected to be published in February 2025 and applications due by June 2025, leading to funding decisions anticipated in February 2026. Interested applicants should prepare their proposals in advance of these deadlines.
    Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)." This initiative invites applications that focus on the neurological and mental health manifestations associated with chronic illnesses resulting from infections, particularly the post-acute sequelae of COVID-19 (Neuro-PASC) and other conditions with potential infectious triggers. The funding aims to advance research into the mechanisms underlying these conditions, including neuroinflammation and brain dysfunction, with an emphasis on stakeholder engagement from underserved populations. Applications are due by November 6, 2025, with budgets capped at $500,000 annually and project durations of up to five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for pilot projects aimed at enhancing the Human Virome Program through a grant titled "Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed)." This initiative seeks to support small businesses in developing innovative projects that advance the understanding of the healthy human virome, including its characterization, tools, and interactions with the host, while ensuring that proposed projects do not overlap with existing efforts. With an estimated total program funding of $2,000,000 and the expectation of awarding six grants, interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published on September 15, 2025. For further inquiries, potential applicants can contact Amanda Melillo, PhD, at amanda.melillo@nih.gov or by phone at 301-529-7217.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infection in cancer development. This initiative encourages mechanistic and epidemiologic studies that explore how infections by multiple agents—both pathogenic and non-pathogenic—can influence cancer risk and progression, with a focus on known oncogenic agents, excluding HIV. Given the significant proportion of cancer cases linked to infectious agents, this research is crucial for developing novel prevention and treatment strategies. Interested applicants, including a variety of educational institutions and organizations, particularly those from underrepresented groups, must submit their applications by November 5, 2025, and can find further details and guidelines at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov.
    NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is inviting applications for the Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) grant. This funding opportunity aims to support multi-project research initiatives that focus on infectious, immunologic, and allergic diseases, requiring each application to include at least two synergistic research projects and an administrative core, all centered around a common theme. The initiative is crucial for advancing research in areas such as the biology and pathogenesis of infectious microbes, immune system mechanisms, and the development of vaccines and therapeutics. Interested applicants must submit their proposals electronically via Grants.gov by September 7, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The funding amount is not limited but should reflect the actual needs of the proposed projects.
    NHLBI Program Project Applications (P01 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Program Project (P01) grant applications aimed at advancing research in heart, lung, and blood diseases. Applicants are required to submit proposals that include a minimum of three interrelated research projects focused on a common biomedical theme, with the option to incorporate clinical trials. This initiative is designed to foster collaborative research efforts and encourage innovative scientific directions, particularly supporting projects led by Early Stage Investigators (ESIs). The maximum funding for awarded projects is capped at $1.515 million annually, or $1.765 million if an ESI-led project is included, with a project duration of up to five years. Interested applicants can find more information and submit their proposals electronically via Grants.gov, with a closing date for applications set for September 25, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.